Sign inJoin waitlistJoin the waitlist

AM

Amitabha Mazumder

Physician · Starling Oncology

Credentials: · · · ·

History

Starling Oncology
Present

National Cancer Center Medical Oncology
1981–1983
Baylor College of Medicine
1977–1979
Johns Hopkins Univ Sch of Med
1973–1977

Research

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
The Journal of Experimental Medicine · 1982 · 2,506 citations
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Blood · 2010 · 728 citations
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
The Lancet · 2016 · 711 citations

Sundar Jagannath
28 papers
David Vesole
19 papers
UV
Udit Verma
18 papers · 2 as a resident
RA
Ravin Agah
15 papers · 1 as a resident
Kenneth Meehan
13 papers
Paul Richardson
12 papers
Saul Rosenberg
10 papers
Ken Anderson
9 papers
BD
Brian Durie
8 papers
Madhav Dhodapkar
7 papers
Sagar Lonial
7 papers
RB
Russell Brynes
6 papers

Grants

Immunotherapy of Cancer by Lymphokine-Activated Cells
National Cancer Institute · K04
Contact PI · $242.5K · University of Southern California
1985–1990
Immunotherapy of Cancer by Lymphokine-Activated Cells
National Cancer Institute · R01
Contact PI · $184.9K · University of Southern California
1985–1988
Immunotherapy of Cancer by Lymphokine-Activated Cells
National Cancer Institute · R01
Contact PI · $31.9K · Baylor College of Medicine
1985
Immunotherapy of Cancer by Lymphokine-Activated Cells
National Cancer Institute · K04
Contact PI · $25.5K · Baylor College of Medicine
1985

Clinical trials

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
Principal investigator · Terminated · Phase 1, Phase 2
NYU Langone Health
2014–2015
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
Principal investigator · Terminated · Phase 2
NYU Langone Health
2013–2015
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Principal investigator · Terminated · Phase 2
NYU Langone Health
2011–2015
A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
Principal investigator · Terminated · Phase 2
NYU Langone Health
2011–2013